ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2023, Vol. 15 ›› Issue (6): 540-544.

• 临床研究 • 上一篇    下一篇

不同剂量重组人干扰素α2b对毛细支气管炎患儿血清沉默信息调节因子1水平的影响

  

  • 出版日期:2023-12-25 上线日期:2024-03-06

Effect of different doses of recombinant human interferon α 2b on serum SIRT1 levels in children with bronchiolitis

  • Published:2023-12-25 Online:2024-03-06

PDF (PC)

8

摘要： 目的 探究不同剂量重组人干扰素α2b(rhIFNα2b)对毛细支气管炎患儿血清沉默信息调节因子1(SIRT1)水平的影响。方法 选取2021年4月至2022年4月本院收治的毛细支气管炎患儿102例，随机分为对照组和观察组各51例。两组均接受常规基础治疗，对照组在常规治疗的基础上雾化吸入rhIFNα2b注射液每次10万IU/kg,观察组则雾化吸入rhIFNα2b注射液每次20万IU/kg,两组均治疗5 d。对比两组治疗前、5 d后临床症状评分、症状体征消失时间、肺功能指标、血气指标、SIRT1及细胞免疫指标水平的差异性，并评价治疗的安全性。结果 5 d后，观察组患儿咳嗽、喘息、哮鸣音以及三凹征临床症状评分均低于对照组，差异有统计学意义(P<0.05)。观察组各临床指标消失时间以及住院时间均较对照组更短，差异有统计学意义(P<0.05)。5 d后，观察组患儿峰流速、潮气量、达峰时间比、血氧饱和度、动脉血氧分压以及SIRT1均较对照组更高，其呼吸阻力、二氧化碳分压、嗜酸性粒细胞以及嗜酸性粒细胞阳离子蛋白均较对照组更低，差异有统计学意义(P<0.05)。结论 rhIFNα2b治疗小儿毛细支气管炎疗效显著且安全，且和每次10万IU/kg雾化吸入剂量相比，每次20万IU/kg雾化吸入剂量在缓解患儿临床症状与体征、改善肺功能及血气情况、调节机体免疫与SIRT1水平方面效果更佳。

关键词: 毛细支气管炎, 重组人干扰素α2b, 血清沉默信息调节因子1, 雾化吸入, 预后

Abstract: ObjectiveTo investigate the effects of different doses of recombinant human interferon α2b (rhIFNα2b) on serum silent information regulator 1 (SIRT1) levels in children with capillary bronchitis.MethodsTotally 102 children with bronchiolitis admitted to our hospital from April 2021 to April 2022 were randomly divided into a control group and an observation group,with 51 cases in each group.Both groups received routine basic treatment;additionally,the control group received nebulized inhalation of rhIFN α2b injection at 100 000 IU/(kg·dose),while the observation group received nebulized inhalation of rhIFN α2b injection at 200 000 IU/(kg·dose),both being treated for 5 days.Compare the differences in clinical symptom scores,disappearance time of symptoms and signs,lung function indicators,blood gas indicators,SIRT1 and cellular immune indicators between the two groups before and 5 days after treatment,and evaluate the safety of treatment.ResultsAfter 5 days of treatment,the clinical symptom scores of cough,wheezing,wheezing rale,and triple concave syndrome in the observation group were lower than those in the control group (P<0.05).The disappearance time of various clinical indicators and hospitalization time in the observation group were shorter than those in the control group(P<0.05).After 5 days of treatment,PTEF,VT,TPTEF/TE,SaO2,PaO2,and SIRT1 in the observation group were higher than those in the control group,and their Rrs,PaCO2,EOC,and ECP were lower than those in the control group(P<0.05).ConclusionThe rhIFNα2b is effective and safe in the treatment of pediatric capillary bronchitis,and compared with 100 000 IU/(kg·dose),200 000 IU/(kg·dose) is more effective in relieving clinical symptoms and signs,improving lung function and blood gas,regulating body immunity and SIRT1 levels.

Key words:

Capillary bronchitis, Recombinant human interferon α2b, Serum silencing information regulator 1, Nebulised inhalation, Prognosis